When he first stepped into the field of glycoproteomics, particularly the potential of truncated O-glycans as cancer targets, Constantine Theodoropulos, CEO of Go Therapeutics Inc., said the reaction from peers was less than encouraging. “They said, ‘You’re nuts, it’s too complicated.’” Now, however, the company he co-founded has landed a deal with Astellas Pharma Inc.’s immuno-oncology-focused subsidiary, Xyphos Biosciences Inc., that brings $20.5 million up front, with the potential for up to $763 million in milestone and contingency payments down the road. Read More
I-Mab Biopharma Co. Ltd. chief medical officer John Hayslip said the firm is “moving forward at our best speed” in tandem with partner Shanghai Junshi Biosciences Co. Ltd. to produce a diagnostic test that could be used in further clinical work with anti-CD73 antibody uliledlimab, for which results from an ongoing phase II trial were disclosed May 26. Read More
Pivotal in killing the Biden administration’s Build Back Better budget legislation, Sen. Joe Manchin (D-W.Va.) is now working to revive parts of it, including the provision that would require Medicare to directly negotiate prescription drug prices. Read More
Healiva SA, a Swiss wound care specialist, emerged from stealth mode having acquired two cell therapy assets from Smith & Nephew plc. Financial terms were not disclosed, but they included an up-front payment as well as “deferred benefits,” Healiva CEO and founder Priyanka Dutta-Passecker told BioWorld. The deal means that the Lugano-based company – which was formed in 2020 – could be booking revenues as early as 2023. Read More
Abliva AB has gone above its market capitalization to raise the money it needs to start a phase II/III trial of KL-1333 for the treatment of primary mitochondrial disease. Read More
The U.S. Court of Appeals for the Federal Circuit has ruled again on the appointments clause questions evolving from a patent dispute between Arthrex Inc. and Smith & Nephew Inc., this time in connection with a former acting director of the Patent and Trademark Office (PTO). Read More
New hires and promotions in the biopharma industry, including: AGTC, Aqilion, Black Diamond, Gentibio, Innovent, Onconano, Oramed, Passage, Rezolute, Sensei, SQZ, Summit, Valneva. Read More
New and updated preclinical and clinical data to be presented by biopharma firms at American Society of Clinical Oncology annual meeting, including: Cullinan, Enlivex, Gritstone, Inxmed. Read More
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Achieve, Alpine, Aruna, Asher, Astellas, Cocrystal, Coda, GSK, ICER, Merck, Neuexcell, Orphazyme, Scineuro, Theolytics and Virios. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: 180 Life Science, Argenx, Astrazeneca, Avillion, Bristol Myers Squibb, Cybin, FSD, Genentech, Iaso, Innovent, Janux, Lexicon, Novartis, Oncomatryx, Outlook, PDS, Priothera, Regeneron, Sanofi, Stealth, TG, Timber, Tscan, United, Y-mabs. Read More
